How Do 510(k), De Novo, and PMA Regulatory Pathways Compare?

The three main routes to market a medical device in the United States are the 510(k) premarket notification, the De Novo classification request, and premarket approval. Risk class and the existence of a legally marketed predicate decide which applies, per FDA's pathway pages. Most devices enter through 510(k); Class III devices require PMA.

What is the 510(k) pathway and when does it apply?

A 510(k) is a premarket submission that demonstrates a device is substantially equivalent to a legally marketed predicate device. Per FDA's premarket notification page, each person who wants to market a Class I, II, or III device for human use, for which a PMA is not required, must submit a 510(k) unless the device is exempt. Substantial equivalence means the device has the same intended use and either the same technological characteristics as the predicate, or different characteristics that do not raise new questions of safety and effectiveness.

The route is fast and evidence-light relative to PMA, typically resting on bench performance testing rather than clinical trials. Since October 1, 2023, all 510(k) submissions, unless exempted, must be submitted as electronic submissions using eSTAR, FDA's structured template. The clearance order arrives as a letter finding the device substantially equivalent; a sponsor may market only after receiving that order.

When does a device need the De Novo route?

The De Novo request exists for novel devices with no predicate. Per the De Novo classification request page, the pathway classifies novel devices for which general controls, or general and special controls, provide reasonable assurance of safety and effectiveness, but for which there is no legally marketed predicate device. It is a risk-based classification process that places a device into class I or class II rather than leaving it in class III.

De Novo is the pathway that creates new device categories. A granted request not only authorizes marketing but establishes a new classification that future 510(k) submissions can use as a predicate, which is how categories such as digital health sensors and novel diagnostics accumulate followers. Since October 1, 2025, De Novo requests, unless exempted, must be submitted electronically using eSTAR, per the same page. The evidence package typically includes clinical data where the risk profile warrants it, making De Novo more demanding than a 510(k) but far less than a PMA.

What does PMA require and for which devices?

Premarket approval is the FDA process of scientific and regulatory review to evaluate the safety and effectiveness of Class III medical devices, per the PMA page. Class III devices are those that support or sustain human life, are of substantial importance in preventing impairment of human health, or present a potential unreasonable risk of illness or injury. FDA has determined that general and special controls alone are insufficient for these devices, so the PMA application must carry the full evidentiary weight.

In practice that means extensive nonclinical laboratory studies, usually one or more clinical investigations with a defined primary endpoint, and manufacturing quality information. PMA also carries ongoing obligations after approval: annual reports, and supplements or amendments for significant changes to the device or its labeling. It is the longest and most expensive route, reserved for the highest-risk technology.

How do the three pathways line up side by side?

The comparison comes down to trigger, evidence, and output.

How does a sponsor choose correctly?

The decision sequence is mechanical. First, check whether the device type is already classified and whether an exemption applies. Second, search for predicates of the same intended use; if one exists and the technological differences do not raise new questions, 510(k) applies. Third, if no predicate exists but the risk is low-to-moderate, De Novo is the route. Fourth, if the device falls into a class III designation regulation or is life-sustaining of high importance, PMA applies. FDA's classification databases and pre-submission meetings are the tools that settle borderline cases before a sponsor commits to an evidence plan, and the eSTAR template now structures all three submission types.

What happens after authorization on each pathway?

The pathway does not end at the authorization letter. A 510(k) clearance obliges the manufacturer to general controls and to new submissions for significant changes that could affect safety or effectiveness. A De Novo grant carries the special controls written into the new classification regulation, which followers must meet as well. A PMA approval carries the heaviest postmarket regime: annual reports to FDA, and supplements for most changes to the device, its labeling, or its manufacturing site.

The asymmetry is deliberate. The premarket evidence burden rises with risk, and so does the postmarket surveillance burden. A cleared Class II device typically reports through establishment registration, medical device reporting, and complaints; an approved Class III device lives under continuous FDA visibility. Sponsors planning a portfolio should model the postmarket cost at selection time, not after authorization.

Inspection exposure differs as well. PMA sites are subject to statutory preapproval inspection, while 510(k) manufacturers are inspected under the quality system regulation on a risk-based schedule. The pathway choice therefore propagates into the operational footprint of the company long after the submission decision is forgotten.

What are the classic selection mistakes?

The first mistake is misreading the predicate. A device with the same intended use but a different mechanism of action may still be substantially equivalent if the differences do not raise new questions of safety and effectiveness, but that judgment belongs to FDA, not to the sponsor's optimism. Choosing a weak predicate to shortcut evidence is how submissions end in not substantially equivalent letters.

The second mistake is treating De Novo as a fallback for a failed 510(k). The pathways are procedurally linked: a 510(k) found not substantially equivalent can, in the same device's case, convert into a De Novo request. But a De Novo still requires the risk-benefit evidence appropriate to a novel device, so the route saves time only when the device genuinely fits low-to-moderate risk.

The third mistake is underestimating PMA scope. A Class III determination can arrive through a classification regulation or through FDA's device-type decisions, and it applies to the device type, not to an individual sponsor. Teams that plan for 510(k)-level evidence on a Class III type discover the gap at pre-submission, which is late but survivable; discovering it at submission is not.

Why does pathway fluency matter commercially?

Pathway determines clock time, evidence cost, and what marketing claims the label can carry. Clearance by substantial equivalence anchors the new device to the predicate's claims; De Novo writes a new intended use from scratch; PMA approves a specific set of indications supported by clinical data. Reimbursement conversations inherit all three differences.

For investors and corporate development teams, the first diligence question for any device program is therefore not whether it works but which door it enters through and what stands between it and that door: a predicate search, a classification question, or a full clinical program. FDA's own pathway pages, including the three cited here, are written for exactly that reading, and the eSTAR template makes the agency's expected structure visible before a single document is drafted.